Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

Supportive Care in Cancer

Volumn 18, Issue 9, 2010, Pages 1171-1177

  Hesketh, Paul J ^a   Aapro, Matti ^b   Street, James C ^c   Carides, Alexandra D ^d  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c Reagent   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Aprepitant; Chemotherapy; Cisplatin; Emesis; Risk factor

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CISPLATIN; DEXAMETHASONE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PLACEBO;

ADULT; AGED; AGING; ALCOHOL CONSUMPTION; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; PREDICTIVE VALUE OF TESTS; RISK FACTORS; VOMITING;

EID: 77956458957     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0737-9     Document Type: Article

References (17)

1. Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T (2007) Chemotherapyinduced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 5:374-380
2. D'Acquisto R, Tyson LB, Gralla RJ (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257
3. Herrstedt J, Roila F (2008) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 19 (Suppl 2): ii110-ii112
4. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191-196
5. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebocontrolled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J Clin Oncol 21:4112-4119
6. Hesketh PJ, Plagge P, Bryson JC (1992) Single-dose ondansetron for prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In: Bianchi AL, Grelot L, Miller AD (eds) Mechanisms and control of emesis. Libbey, London, pp 25-26
7. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:29322947
8. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116-123
9. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapyinduced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
10. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64:1117-1122
11. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
12. Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, Malacarne P, Monici L, Di Costanzo F, Patoia L et al (1989) Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian oncology group for clinical research. J Clin Oncol 7:1693-1700 (Pubitemid 19272841)
13. Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol 5:5-12
14. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219-227
15. Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2:107-114
16. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit R, Carides AD, Taylor A, Evans JK, Horgan KJ (2005) The oral NK (1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41:1278-1285
17. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapyinduced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830 (Pubitemid 46179473)